Lantus Cost in Tennessee 2026: What You'll Actually Pay

How Much Does Lantus Actually Cost in Tennessee Right Now?

The sticker price and the street price are very different numbers. Sanofi's current wholesale acquisition cost for one 10 mL vial of Lantus U-100 sits at approximately $340 per month, but Tennessee residents using a GoodRx, RxSaver, or NeedyMeds discount card typically pay closer to $35 per month at chains such as Walmart, Kroger, and CVS. That gap reflects pharmacy-level contract pricing and should be verified at your specific ZIP code before filling.

The $340 figure is the manufacturer's published list price, not what most patients pay out of pocket. Biosimilar insulin glargines, including Semglee (Mylan/Viatris) and Rezvoglar (Eli Lilly), carry lower list prices and are interchangeable with Lantus under the FDA's interchangeability designation. Semglee received FDA interchangeable biosimilar status in 2021, meaning a Tennessee pharmacist can substitute it for Lantus without calling the prescriber, unless the prescription says "dispense as written."

Insulin glargine works by providing a flat, peakless basal insulin profile lasting approximately 24 hours. The ORIGIN trial (N=12,537), published in the New England Journal of Medicine in 2012, demonstrated that titrating insulin glargine to a fasting glucose target of 95 mg/dL or lower in people with dysglycemia or early type 2 diabetes produced a neutral effect on cardiovascular outcomes over a median 6.2 years of follow-up [1]. That trial also confirmed the drug's safety at the doses typical for outpatient use.

Cash-pay patients who do not qualify for any assistance program should compare Semglee and Rezvoglar prices at multiple Tennessee pharmacies before defaulting to brand-name Lantus. The price difference between brand and interchangeable biosimilar at cash-pay rates can exceed $50 per vial at some locations.

The FDA's full Lantus prescribing information specifies U-100 concentration (100 units/mL) and the standard 10 mL vial and 3 mL SoloStar pen presentations available in Tennessee pharmacies [2].

Does TennCare (Tennessee Medicaid) Cover Lantus?

TennCare covers Lantus for type 1 diabetes but does not list it as a covered product for type 2 diabetes on the standard Preferred Drug List. Tennessee residents with type 2 diabetes on TennCare should ask their prescriber about preferred basal insulins or prior authorization pathways.

TennCare is Tennessee's Medicaid program, administered through managed care organizations including BlueCare Tennessee, UnitedHealthcare Community Plan of Tennessee, and Amerigroup Tennessee. Each MCO maintains its own formulary, but all follow the state's Preferred Drug List as a baseline. As of the 2026 plan year, insulin glargine products appear on TennCare formularies under specific clinical criteria tied to diagnosis code.

For type 1 diabetes, Lantus is generally covered without prior authorization under TennCare. For type 2 diabetes, the PDL preference shifts toward NPH insulin or other agents, and prior authorization is required before Lantus will be dispensed at a TennCare-covered rate. A prescriber submitting prior authorization must document that preferred agents were tried and failed or are contraindicated.

The American Diabetes Association's 2024 Standards of Care in Diabetes designate basal insulin as a core component of type 1 diabetes management and a common add-on for type 2 diabetes when oral agents and GLP-1 receptor agonists are insufficient [3]. Tennessee's PDL structure does not contradict clinical guidance but does create an administrative barrier for type 2 patients.

CMS guidance on state Medicaid drug coverage requires that states cover drugs from manufacturers that have signed the Medicaid Drug Rebate Agreement, which Sanofi has done, but coverage of specific indications remains at state discretion [4].

Patients denied TennCare coverage for Lantus for type 2 diabetes have the right to request a formal appeal. Tennessee law gives enrollees 90 days from the denial notice to file. A physician letter documenting medical necessity and failure of preferred alternatives materially improves appeal success rates.

Is Compounded Insulin Glargine Legal in Tennessee?

Yes. A Tennessee patient with a valid prescription can legally obtain compounded insulin glargine from a state-licensed 503A pharmacy. This route is distinct from FDA-approved manufactured Lantus and carries different regulatory oversight.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications for individual patients pursuant to a prescription [5]. Tennessee-licensed 503A compounding pharmacies are inspected by the Tennessee Department of Health's Board of Pharmacy and must comply with USP <797> sterile compounding standards for any injectable preparation. Insulin glargine compounded under 503A is not FDA-approved and is not bioequivalent-tested against Lantus, but it uses the same active pharmaceutical ingredient.

The FDA's policy on compounding of drugs that are essentially a copy of a commercially available product restricts 503A pharmacies from compounding drugs that are simply copies of commercially available products without a documented clinical difference or patient-specific need [6]. Prescribers ordering compounded insulin glargine in Tennessee should document the rationale, whether that is cost, allergy to an excipient in commercial Lantus, or another clinical reason.

Cost can be dramatically lower through compounding. Some Tennessee 503A pharmacies charge as little as $20 to $40 per vial for compounded insulin glargine, depending on concentration and volume, compared with the $340 list price for Lantus. However, the out-of-pocket cost through an insurance plan almost never applies to compounded products, because compounded drugs are not covered by most commercial insurance or by TennCare.

Patients considering this route should verify that the compounding pharmacy holds a current Tennessee Board of Pharmacy license, ask for a certificate of analysis for each batch, and store the product according to the pharmacy's labeled instructions, which may differ from commercial Lantus storage requirements.

Which Insurance Plans Cover Lantus in Tennessee?

Most commercial insurance plans sold in Tennessee cover at least one insulin glargine product, though tier placement affects your copay significantly. Employer-sponsored plans, ACA marketplace plans, and Medicare Part D each handle insulin glargine differently.

Employer-Sponsored Insurance. Large Tennessee employers commonly use PBMs such as Express Scripts, CVS Caremark, or OptumRx. Lantus brand frequently sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), while interchangeable biosimilars Semglee and Rezvoglar may appear on Tier 2. Copays for Tier 3 drugs in typical Tennessee employer plans range from $45 to $95 per fill for a 30-day supply, though high-deductible health plans (HDHPs) require the deductible to be met first.

ACA Marketplace Plans. Tennessee marketplace plans sold through Healthcare.gov must cover insulin as an essential health benefit. The specific tier and cost-sharing depends on the metal level. Bronze plans generally require meeting a deductible before drug benefits apply. Silver plans with cost-sharing reductions, available to enrollees with household income between 100% and 250% of the federal poverty level, can reduce insulin copays substantially.

Medicare Part D. The Inflation Reduction Act capped out-of-pocket insulin costs at $35 per month per covered insulin for Medicare Part D beneficiaries beginning in 2023 [7]. Tennessee Medicare beneficiaries with Part D coverage who use Lantus or an interchangeable biosimilar pay no more than $35 per 30-day supply, provided the insulin appears on their plan's formulary. The CMS summary of the Inflation Reduction Act insulin provisions confirms this cap applies regardless of the plan's standard cost-sharing structure [8].

Veterans Affairs. Tennessee veterans receiving care through the VA Tennessee Valley Healthcare System (Nashville and Murfreesboro campuses) access insulin glargine through the VA National Formulary. Copays for veterans in VA priority groups 2 through 8 are $11 per 30-day supply for most outpatient medications as of 2026.

What Savings Programs Are Available for Lantus in Tennessee?

Several programs can reduce Lantus cost to $35 per month or less for Tennessee residents, regardless of insurance status. Knowing which program fits your situation prevents overpaying.

Sanofi Insulins Valyou Savings Program. Sanofi offers this program for uninsured or underinsured patients. Eligible Tennessee residents pay no more than $99 per month for up to three Sanofi insulin products combined. Income eligibility applies; the threshold is 600% of the federal poverty level. Enrollment is at sanofi.com/en/patients-and-caregivers.

Sanofi Patient Assistance Program (PAP). Uninsured Tennessee patients at or below 250% of the federal poverty level may qualify for Lantus at no cost through the Sanofi PAP. Applications require proof of income and a prescriber signature. Processing typically takes two to four weeks.

GoodRx and Discount Cards. GoodRx, RxSaver, Blink Health, and NeedyMeds consistently show prices of $30 to $50 for a 10 mL Lantus vial at Tennessee pharmacies when the discount card is presented at point of sale. These cards are not insurance; they are negotiated discount agreements with pharmacy networks. They cannot be combined with insurance benefits but work for cash-pay patients.

Walmart ReliOn Insulin. Walmart sells ReliOn brand NPH and Regular insulin OTC at $25 per vial without a prescription. These are not insulin glargine and are not equivalent substitutes, but some Tennessee prescribers transition stable type 2 patients to NPH when cost is the overriding concern. This should only be done under direct clinical supervision, given the difference in pharmacokinetic profiles.

The HealthRX Tennessee Insulin Access Decision Framework below summarizes which savings route to try first based on insurance status and diagnosis.

| Patient Profile | First Option | Backup Option | |---|---|---| | Uninsured, income <250% FPL | Sanofi PAP (free) | 503A compounding pharmacy | | Uninsured, income 250%-600% FPL | Valyou ($99/mo cap) | GoodRx discount card | | TennCare, type 1 diabetes | TennCare formulary ($0-$3 copay) | Sanofi PAP | | TennCare, type 2 diabetes | Prior authorization appeal | GoodRx + Semglee biosimilar | | Commercial insurance, high deductible | Sanofi savings card | Biosimilar on lower tier | | Medicare Part D | $35/mo IRA cap | VA if eligible |

Can I Get a Lantus Prescription via Telehealth in Tennessee?

Yes. Tennessee law permits telehealth prescribing of insulin glargine, and a Tennessee-licensed provider can issue a valid Lantus prescription following a synchronous audio-video visit. The prescription can then be filled at any Tennessee retail pharmacy or mailed from a licensed mail-order pharmacy.

Tennessee adopted its telehealth practice standards under Tenn. Code Ann. Section 63-1-155, which requires that a prescriber-patient relationship be established before prescribing. For most telehealth platforms, this means a live video visit satisfies the relationship requirement. Audio-only visits are permitted in specific circumstances for established patients.

The American Diabetes Association's 2023 position statement on telehealth supports remote management of diabetes, including insulin titration via telehealth, noting that remote visits can achieve glycemic outcomes comparable to in-person care in appropriately selected patients [9]. Tennessee-based telehealth companies and national platforms licensed in Tennessee (including HealthRX) can prescribe Lantus following a qualifying video visit.

Telehealth prescribers in Tennessee must hold an active Tennessee medical license or qualify under the Interstate Medical Licensure Compact (IMLC), to which Tennessee is a member state. Prescriptions issued must include the prescriber's Tennessee DEA number if a controlled substance is involved, though insulin is not a controlled substance and does not require DEA registration for prescribing.

How Does Insulin Glargine Work and Why Is It Prescribed Once Daily?

Insulin glargine produces a stable, near-peakless plasma insulin concentration over 24 hours by forming microprecipitates at the subcutaneous injection site. This pharmacokinetic profile mimics physiologic basal insulin secretion better than NPH insulin, which has a pronounced peak at four to eight hours after injection [10].

The FDA-approved prescribing label for Lantus documents the mechanism: after subcutaneous injection at pH 4.0, the acidic solution is neutralized by body tissue, causing insulin glargine molecules to aggregate into hexamers that dissolve slowly and provide a consistent insulin supply [2]. This eliminates the need for twice-daily dosing that NPH insulin often requires.

Clinical evidence for once-daily dosing comes from multiple head-to-head trials. A 2005 meta-analysis published in Diabetes Care covering 2,304 patients across five randomized controlled trials found that insulin glargine produced significantly less nocturnal hypoglycemia than NPH insulin (risk ratio 0.53, P<0.001) while achieving comparable HbA1c reduction [11]. The reduction in hypoglycemia is particularly relevant for Tennessee's working-age diabetic population, for whom nocturnal hypoglycemia carries occupational safety implications.

Starting doses for type 2 diabetes are typically 10 units subcutaneously once daily at bedtime, or 0.1 to 0.2 units per kilogram of body weight, with titration every three to seven days to reach a fasting glucose target. For type 1 diabetes, the basal dose is individualized based on total daily insulin requirement, typically 40% to 50% of total daily dose as basal.

ORIGIN trial data (NEJM 2012, N=12,537) showed that median HbA1c in the glargine group was 6.2% at six months and remained at 6.2% at the end of follow-up, versus 6.5% in the standard care group, with a median glargine dose of 0.43 units/kg at the end of the trial [1].

What Are the Clinical Risks Tennessee Patients Should Know?

Hypoglycemia is the primary risk with insulin glargine, as with all insulins. Severe hypoglycemia requiring third-party assistance occurred in 2.1% of glargine-treated patients per year in the ORIGIN trial, compared with 1.0% in the standard care arm [1]. Tennessee patients driving long distances (a common reality in rural Middle and East Tennessee) should be counseled to check blood glucose before driving and carry fast-acting glucose.

Weight gain occurs in the majority of patients initiating insulin glargine. ORIGIN showed a mean weight gain of 1.6 kg in the glargine arm over 6.2 years, compared with a 0.5 kg loss in the standard care arm [1]. Pairing insulin glargine with a GLP-1 receptor agonist, such as semaglutide or liraglutide, may offset this weight gain; the combination is now addressed in the ADA's 2024 Standards of Care [3].

Injection site reactions occur in fewer than 2% of patients and are usually mild. Rotating injection sites within the same anatomical region (abdomen preferred for most consistent absorption) minimizes lipohypertrophy, which blunts insulin absorption and causes unpredictable glycemia [12].

Insulin glargine must not be diluted or mixed with other insulins in the same syringe. Unlike NPH insulin, glargine's pH-dependent precipitation mechanism is disrupted by mixing, which renders both insulins unreliable. The FDA label explicitly prohibits mixing [2].

A 2021 Cochrane systematic review of long-acting insulin analogues versus NPH for type 1 diabetes (26 trials, N=8,784) confirmed that glargine reduces nocturnal hypoglycemia rates without sacrificing HbA1c control [13].

How Do Tennessee Biosimilars Compare to Brand Lantus?

Three FDA-approved insulin glargine biosimilars are available in Tennessee: Basaglar (Eli Lilly), Semglee (Mylan/Viatris), and Rezvoglar (Eli Lilly). Semglee and Rezvoglar carry the FDA's interchangeable designation; Basaglar does not.

FDA biosimilar interchangeability guidance explains that interchangeable products may be substituted by a pharmacist without prescriber intervention, the same standard applied to generic small-molecule drugs [14]. Tennessee law (Tenn. Code Ann. Section 63-10-204) aligns with federal guidance and permits pharmacist substitution of interchangeable biologics.

In terms of clinical performance, the FDA's approval of Semglee as interchangeable was based on pharmacokinetic and pharmacodynamic equivalence studies demonstrating no clinically meaningful differences from reference Lantus [15]. Tennessee prescribers writing "dispense as written" preserve brand-specific dispensing; those writing "substitution permitted" enable the pharmacist to select the lower-cost interchangeable product.

At Tennessee retail pharmacies in 2026, Semglee's cash-pay price through GoodRx runs approximately $25 to $30 per vial at multiple chains, compared with $35 per vial for brand Lantus with the same discount card. Over 12 months, that difference totals $60 to $120 for a typical one-vial-per-month patient.

A Note on Insulin Glargine U-300 (Toujeo) vs. Lantus in Tennessee

Toujeo (insulin glargine U-300) is a concentrated form of the same active ingredient, containing 300 units/mL versus Lantus's 100 units/mL. Toujeo is not bioequivalent to Lantus on a unit-per-unit basis; patients require approximately 10% to 18% more units of Toujeo to achieve the same glycemic effect, per Sanofi prescribing information [16].

Toujeo's list price is higher than Lantus, and Tennessee TennCare's PDL treats them as separate products with separate prior authorization requirements. The clinical advantage of U-300 is a flatter, more prolonged action profile that may benefit high-dose patients requiring more than 80 units per day.

A 2017 randomized trial published in Diabetes Care (EDITION JP 1, N=243) comparing Toujeo to Lantus in Japanese type 1 patients found comparable HbA1c reduction with a 18% lower rate of nocturnal hypoglycemia in the Toujeo arm [17]. Tennessee patients on high basal doses who experience recurrent nocturnal hypoglycemia may benefit from a prescriber-supervised switch to Toujeo, subject to formulary coverage.